Moderna, Inc. announced a significant milestone in cancer research with the dosing of the first patient in a Phase 1/2 clinical study of its investigational mRNA-based T-cell engager, designated mRNA-2808. This event took place on November 3, 2025, at SCRI Oncology Partners in Nashville, Tennessee, in collaboration with the Sarah Cannon Research Institute.
The study aims to evaluate the safety and efficacy of mRNA-2808 in patients suffering from relapsed or refractory multiple myeloma (RRMM). This condition is known for its aggressive nature and challenges in treatment. The innovative therapy encodes three T-cell engagers that specifically target validated myeloma-associated antigens. By employing this multiplexed approach, Moderna hopes to tackle tumor heterogeneity and address mechanisms that contribute to target-mediated resistance.
Understanding mRNA-2808’s Potential
Moderna’s approach with mRNA-2808 represents a pioneering effort in the field of oncology. The therapy’s design allows it to engage the patient’s immune system more effectively against multiple myeloma cells. This investigational treatment could transform the landscape for patients who have exhausted other options, as RRMM is notoriously difficult to treat.
According to the company, the Phase 1/2 trial is essential for assessing both the safety profile and the biological activity of mRNA-2808. The study will enroll multiple participants across various sites, with the ultimate goal of determining the optimal dosing regimen and potential clinical benefits for those impacted by this challenging disease.
Collaborative Efforts in Cancer Research
The involvement of SCRI Oncology Partners and the Sarah Cannon Research Institute underscores the collaborative nature of this research. These organizations are recognized for their commitment to advancing cancer care through innovative clinical trials. This partnership aims to provide comprehensive support for the trial, ensuring that patients receive cutting-edge therapies in a clinical setting.
As the study progresses, the medical community will closely monitor its outcomes. Should mRNA-2808 demonstrate promising results, it may pave the way for new therapeutic options in the treatment of multiple myeloma, providing hope to many patients facing this formidable illness.
The initiation of this trial marks an important development in Moderna’s expanding portfolio of investigational therapies, further solidifying its role in the fight against cancer and other life-threatening diseases.
